The Puzzle of Familial Hypercholesterolemia

A Practical Guide to Diagnosis and Cascade Screening

Dr Neeraj Manikath , claude.ai

Abstract

Familial Hypercholesterolemia (FH) remains one of the most common yet severely underdiagnosed genetic disorders in medicine, affecting approximately 1 in 250 individuals worldwide. Despite its prevalence and the availability of effective treatments, an estimated 90% of FH cases remain undiagnosed, leading to preventable premature atherosclerotic cardiovascular disease (ASCVD). This review provides a comprehensive, practical approach to recognizing, diagnosing, and implementing cascade screening for FH in clinical practice, with emphasis on actionable strategies for postgraduate physicians in internal medicine.

Introduction: The Hidden Epidemic

Imagine walking past four random people on the street—statistically, one of them likely has hypertension. Now imagine that among every 250 people, one harbors a genetic time bomb that, if left undetected, could trigger a myocardial infarction before age 50. This is the reality of Familial Hypercholesterolemia.

FH is characterized by markedly elevated low-density lipoprotein cholesterol (LDL-C) from birth, resulting in accelerated atherosclerosis and premature coronary artery disease. Without treatment, men with heterozygous FH (HeFH) have a 50% risk of fatal or non-fatal coronary event by age 50, and women by age 60—rates that are 20 times higher than the general population. The tragedy? Early diagnosis and treatment can reduce cardiovascular risk by up to 80%.

Pearl #1: Think of FH screening as secondary prevention masquerading as primary prevention. These patients already have decades of LDL exposure by the time you see them.

The Clinical Criteria: Dutch Lipid Score Made Simple

The Dutch Lipid Clinic Network (DLCN) criteria remain the gold standard for clinical diagnosis of FH, employing a point-based system that integrates family history, clinical history, physical examination findings, and LDL-C levels.

Breaking Down the Dutch Score

1. Family History (0-2 points)

First-degree relative with known premature CAD (men <55 years, women <60 years) OR first-degree relative with known LDL-C >95th percentile: 1 point
First-degree relative with tendinous xanthomata and/or arcus cornealis: 2 points

2. Clinical History (0-2 points)

Patient with premature CAD (men <55 years, women <60 years): 2 points
Patient with premature cerebral or peripheral vascular disease: 1 point

3. Physical Examination (0-6 points)

Tendinous xanthomata: 6 points
Arcus cornealis before age 45 years: 4 points

4. LDL-C Levels (untreated) (0-8 points)

≥330 mg/dL (≥8.5 mmol/L): 8 points
250-329 mg/dL (6.5-8.4 mmol/L): 5 points
190-249 mg/dL (5.0-6.4 mmol/L): 3 points
155-189 mg/dL (4.0-4.9 mmol/L): 1 point

5. Molecular Genetic Testing (0-8 points)

Pathogenic variant in LDLR, APOB, or PCSK9: 8 points

Interpretation:

8 points: Definite FH
6-8 points: Probable FH
3-5 points: Possible FH
<3 points: Unlikely FH

Oyster #1: The Dutch score's greatest weakness is that it requires untreated LDL-C levels. In our statin-saturated world, many patients present already on therapy. Solution: Multiply the on-treatment LDL-C by the expected percent reduction for their statin (e.g., ×2 for moderate-intensity, ×3 for high-intensity statins) to estimate pretreatment values.

Alternative Clinical Tools

The Simon Broome criteria (UK-based) and Make Early Diagnosis to Prevent Early Deaths (MEDPED) criteria (US-based) offer simpler alternatives but may be less sensitive. The Simon Broome criteria require either:

Total cholesterol >290 mg/dL OR LDL-C >190 mg/dL in adults (with age-adjusted cutoffs for children) PLUS tendinous xanthomata in patient or first/second-degree relative, OR
DNA-based evidence of LDLR, APOB, or PCSK9 mutation

Hack #1: For quick bedside assessment, use the "Rule of 190": Any adult with untreated LDL-C ≥190 mg/dL and a family history of premature CAD deserves FH evaluation. For children, use ≥160 mg/dL.

"Severe" Hypercholesterolemia Defined: Monogenic vs. Polygenic Causes

Not all severe hypercholesterolemia is created equal. Understanding the distinction between monogenic FH and polygenic hypercholesterolemia has profound implications for prognosis, family screening, and treatment intensity.

Monogenic FH: The Single-Gene Culprits

True monogenic FH results from single pathogenic variants in genes critical to LDL metabolism:

LDLR (LDL Receptor): 85-90% of genetically confirmed cases. Over 3,000 mutations identified. Results in reduced or absent LDL receptor function, impairing hepatic LDL clearance.

APOB (Apolipoprotein B-100): 5-10% of cases. The p.Arg3527Gln variant is most common. Creates defective apoB protein that cannot bind properly to LDL receptors.

PCSK9 (Proprotein Convertase Subtilisin/Kexin type 9): 1-3% of cases. Gain-of-function mutations cause accelerated LDL receptor degradation, reducing receptor availability.

Rare causes: LDLRAP1 (autosomal recessive hypercholesterolemia), APOE, and STAP1 mutations account for <1% of cases.

Polygenic Hypercholesterolemia: The Cumulative Effect

Polygenic hypercholesterolemia results from the cumulative effect of multiple common LDL-raising variants, each with modest individual effects. Polygenic risk scores can now identify these individuals, who may have LDL-C levels overlapping with monogenic FH but typically:

Have later onset of elevated cholesterol
Show less extreme LDL-C elevations (usually <250 mg/dL)
Lack consistent family history patterns
Have lower cardiovascular risk than monogenic FH patients with equivalent LDL-C levels

Pearl #2: The "LDL-C trajectory" matters. Monogenic FH patients have lifelong exposure from birth. A 45-year-old with newly discovered LDL-C of 210 mg/dL is fundamentally different from someone who had LDL-C >200 mg/dL since childhood.

When to Suspect Monogenic FH

Consider monogenic FH when you encounter:

Untreated LDL-C ≥190 mg/dL in adults or ≥160 mg/dL in children
Tendinous xanthomata (Achilles tendon most common, also extensor tendons of hands)
Premature ASCVD (<55 years men, <60 years women) with elevated LDL-C
Family history of premature CAD or severe hypercholesterolemia
Arcus cornealis <45 years (though less specific than xanthomata)

Hack #2: The "tendon squeeze test": Have patients maximally dorsiflex their foot and palpate the Achilles tendon. Normal tendons are thin (<2 cm width). Xanthomatous tendons feel thickened and irregular. When in doubt, ultrasound or X-ray can reveal increased tendon thickness (>6 mm is abnormal).

The Genetic Test: LDLR, APOB, PCSK9

Genetic testing for FH has transitioned from research tool to clinical standard of care, offering definitive diagnosis, prognostic information, and enabling cascade screening.

Indications for Genetic Testing

According to recent guidelines from the American Heart Association and European Atherosclerosis Society, genetic testing should be offered to:

Individuals with clinical diagnosis of definite or probable FH (Dutch score >6)
Children of known FH patients
Individuals with possible FH when diagnosis would alter management
First-degree relatives of mutation-positive individuals

What Tests to Order

Standard FH Panel: Sequence analysis and deletion/duplication testing of LDLR, APOB, and PCSK9 genes. Many laboratories now offer multigene panels that include rarer causes (LDLRAP1, APOE, STAP1).

Polygenic Risk Scores: Emerging commercial tests can quantify polygenic contribution to elevated LDL-C, helping distinguish polygenic from monogenic causes when genetic testing is negative.

Detection Rate: Genetic testing identifies causative variants in approximately:

80% of definite FH cases (Dutch score >8)
50% of probable FH cases (Dutch score 6-8)
20% of possible FH cases (Dutch score 3-5)

Oyster #2: A negative genetic test does NOT rule out FH. We call these "genetically elusive FH" cases. Reasons include: (1) mutations in unidentified genes, (2) variants in regulatory regions not captured by standard sequencing, (3) mosaicism, or (4) misclassification of polygenic hypercholesterolemia as FH.

Interpreting Genetic Results

Variants are classified according to American College of Medical Genetics criteria:

Pathogenic/Likely Pathogenic: Confirms FH diagnosis
Variant of Uncertain Significance (VUS): Cannot confirm or exclude FH; use clinical criteria
Benign/Likely Benign: Does not explain phenotype; consider alternative diagnoses

Pearl #3: Genotype-phenotype correlations matter. Null LDLR mutations (no receptor function) cause more severe phenotypes than defective mutations (reduced function). APOB mutations typically cause milder phenotypes. This informs treatment intensity.

Practical Considerations

Cost: $250-500 in most US laboratories; often covered by insurance with appropriate ICD-10 coding (E78.01 for FH).

Turnaround time: 2-4 weeks typically.

Pre-test counseling points:

Results have implications for family members
Genetic discrimination protections (GINA in US)
Results may reveal non-paternity
Possible psychological impact

Hack #3: Order genetic testing BEFORE starting high-intensity statins. The clinical phenotype becomes clearer with untreated or minimally treated lipid values, strengthening the pretest probability and improving insurance approval.

Cascade Screening in Action: Systematically Testing First-Degree Relatives

Cascade screening—the systematic identification and testing of relatives of known FH patients—is the most cost-effective strategy for FH detection. For every index case identified, an average of 3-4 affected relatives can be found.

The Evidence Base

The Dutch experience demonstrates cascade screening's power: a national program initiated in 1994 has identified over 50,000 FH patients, achieving an 80% diagnosis rate in some regions. The UK also runs a successful national cascade screening program. Modeling studies show cascade screening costs approximately $4,000 per life-year gained—highly cost-effective by any standard.

Implementing Cascade Screening: A Step-by-Step Protocol

Step 1: Confirm the Index Case Ensure the proband meets definite or probable FH criteria and has undergone genetic testing (if available).

Step 2: Construct a Three-Generation Pedigree Document:

All first-degree relatives (parents, siblings, children)
Ages and vital status
Known lipid levels if available
History of premature ASCVD
Physical findings (xanthomata, arcus)

Step 3: Prioritize Relatives for Testing

High priority:

First-degree relatives of mutation-positive probands
Relatives with known premature ASCVD
Younger relatives (greater potential for prevention)

Medium priority:

Second-degree relatives when first-degree are unavailable or deceased
Children of affected individuals (50% will be affected)

Step 4: Approach and Consent

Provide the index patient with:

A family letter explaining FH and importance of testing
Contact information for genetic counseling
Authorization to release genetic results to relatives

Alternatively, some programs directly contact relatives with index patient permission.

Step 5: Testing Strategy

For relatives of mutation-positive index cases:

Direct genetic testing for the familial mutation (faster, cheaper: $100-200)
If positive: LDL-C measurement and cardiovascular risk assessment
If negative: No further testing needed (unless LDL-C independently elevated)

For relatives of mutation-negative index cases:

LDL-C screening first
If elevated (≥190 mg/dL adults, ≥160 mg/dL children): Full FH evaluation with Dutch criteria
Consider full genetic panel if clinical diagnosis of FH

Step 6: Results Management

Affected relatives need:

Cardiovascular risk assessment (imaging may include coronary calcium scoring, carotid ultrasound)
Lipid-lowering therapy initiation/optimization
Lifestyle counseling
Initiation of their own cascade screening branch

Pearl #4: Children of FH patients should be tested at age 2-10 years. Earlier identification allows earlier dietary intervention and, if needed, pharmacotherapy by age 8-10 years. Don't wait for puberty.

Overcoming Barriers to Cascade Screening

Common obstacles:

Index patient reluctance to contact family: Offer genetic counselor support or clinic-initiated contact
Family estrangement: Document attempted contact; focus on available relatives
Geographic dispersion: Telehealth visits for counseling; coordinate with local providers for testing
Insurance/cost concerns: Many genetic testing companies offer financial assistance; lipid panels are universally covered

Hack #4: Create a "FH Family Screening Kit" in your EMR template that auto-populates: family letter, genetic counseling contact, lab requisition for relatives, and follow-up plan. Make cascade screening systematic, not opportunistic.

Measuring Success

Track cascade screening metrics:

Number of relatives tested per index case (aim for >3)
Percentage of identified relatives who initiate treatment
Time from index case diagnosis to relative testing (aim for <6 months)

Implications for Therapy: The Role of PCSK9 Inhibitors from a Younger Age

FH fundamentally changes the treatment paradigm. These patients require earlier, more aggressive, and often combination lipid-lowering therapy.

Treatment Goals

LDL-C Targets:

Adults with FH, no ASCVD: <100 mg/dL (some guidelines <70 mg/dL)
Adults with FH + ASCVD: <55 mg/dL (<40 mg/dL for very high risk)
Children with FH: <130 mg/dL (some experts advocate <100 mg/dL)

Pearl #5: For FH patients, "normal" LDL-C isn't good enough. Remember: they've had elevated LDL-C since birth. A 40-year-old FH patient has had 40 years of atherogenic exposure—treat them like secondary prevention even if they're asymptomatic.

First-Line Therapy: High-Intensity Statins

Start with high-intensity statins (atorvastatin 40-80 mg or rosuvastatin 20-40 mg daily). Expected LDL-C reduction: 50-60%. However, most FH patients will not reach goal with statin monotherapy.

Hack #5: For FH patients, start high and stay high. Don't step-titrate statins—there's no time to waste. Begin with high-intensity dosing unless contraindicated.

Second-Line: Ezetimibe

Adds 15-20% additional LDL-C lowering to statins. The IMPROVE-IT trial demonstrated cardiovascular benefit. Should be added routinely when statins alone are insufficient.

Game-Changer: PCSK9 Inhibitors

PCSK9 inhibitors (evolocumab, alirocumab) represent a quantum leap in FH management, providing an additional 50-60% LDL-C reduction beyond statins.

Evidence in FH:

ODYSSEY FH trials: Alirocumab reduced LDL-C by 57% in HeFH patients
FOURIER trial: Evolocumab reduced cardiovascular events by 15% over 2.2 years
HAUSER-RCT: Evolocumab effective in homozygous FH with residual LDLR function

Indications for PCSK9 Inhibitors in FH:

According to FDA labeling and major guidelines:

Adults with clinical FH requiring additional LDL-C lowering beyond maximally tolerated statins ± ezetimibe
Adults with clinical FH and established ASCVD
Adolescents ≥10 years with homozygous FH
Increasingly, earlier use in heterozygous FH patients with very high LDL-C (>190 mg/dL on maximal therapy) or other risk factors

Oyster #3: Insurance approval for PCSK9 inhibitors requires documentation gymnastics. Key tips: (1) Document "clinical FH" diagnosis with Dutch score, (2) Show inadequate response to maximally tolerated statin + ezetimibe, (3) Include cardiovascular risk factors, (4) Have genetic testing results if available. Many denials succeed on appeal with additional documentation.

Emerging Therapies

Bempedoic acid: Adds 15-20% LDL-C lowering; useful for statin-intolerant patients. Recent CLEAR Outcomes trial showed cardiovascular benefit.

Inclisiran: Long-acting siRNA targeting PCSK9, dosed twice yearly after loading. Similar efficacy to monoclonal PCSK9 inhibitors; adherence advantage.

Evinacumab: Monoclonal antibody against angiopoietin-like protein 3 (ANGPTL3); approved for homozygous FH with 50% LDL-C reduction.

LDL apheresis: Reserved for homozygous FH or severe HeFH refractory to pharmacotherapy. Requires biweekly sessions; reduces LDL-C by 60-75% per session.

Initiating Therapy in Children

Statins can be safely initiated in children with FH as young as 8-10 years. Evidence from 20+ years of pediatric statin trials shows:

Significant LDL-C reduction (30-40%)
Regression of carotid intima-media thickness
Excellent safety profile (no effects on growth, development, hormones)
No evidence of developmental toxicity

Start with low-dose statin (atorvastatin 10 mg or rosuvastatin 5 mg) and titrate based on response and tolerability. Add ezetimibe if needed.

Pearl #6: The earlier you treat FH, the more dramatic the benefit. A study showed that each year of delay in treatment initiation increased cardiovascular risk by 2-3%. Don't wait for children to "grow out of it"—they won't.

Practical Pearls and Hacks: Summary

Think FH screening as secondary prevention in disguise—these patients have decades of LDL exposure
Use the LDL-C trajectory—lifelong elevation matters more than absolute number
The "Rule of 190"—Any adult with untreated LDL-C ≥190 mg/dL + family history deserves evaluation
Tendon squeeze test for xanthomata detection
Order genetic testing before high-intensity statins to preserve phenotype clarity
Multiply on-treatment LDL-C to estimate pretreatment values for Dutch score
Create FH Family Screening Kits in your EMR
Start high-intensity statins immediately—no step-titration
Document thoroughly for PCSK9 inhibitor approval
Earlier treatment = better outcomes—don't delay therapy in children

Conclusion: From Puzzle to Systematic Approach

Familial Hypercholesterolemia represents one of medicine's greatest opportunities for preventive cardiology. With 90% of cases undiagnosed, every internist has FH patients walking through their door unrecognized. By systematically applying clinical criteria, judiciously using genetic testing, implementing cascade screening, and leveraging modern therapies including PCSK9 inhibitors, we can transform outcomes for these patients and their families.

The puzzle of FH is solvable—it requires only that we look for it. Make FH screening part of your routine practice. The life you save may not only be your patient's, but their children's and grandchildren's as well.

References

Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Eur Heart J. 2013;34(45):3478-3490.
Gidding SS, Champagne MA, de Ferranti SD, et al. The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association. Circulation. 2015;132(22):2167-2192.
Cuchel M, Bruckert E, Ginsberg HN, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. Eur Heart J. 2014;35(32):2146-2157.
Talmud PJ, Shah S, Whittall R, et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia. Lancet. 2013;381(9874):1293-1301.
Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ, et al. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet. 2001;357(9251):165-168.
Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-1722.
Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379(22):2097-2107.
Luirink IK, Wiegman A, Kusters DM, et al. 20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia. N Engl J Med. 2019;381(16):1547-1556.
Khera AV, Won HH, Peloso GM, et al. Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. J Am Coll Cardiol. 2016;67(22):2578-2589.
Raal FJ, Hovingh GK, Blom D, et al. Long-term Treatment with Evolocumab Added to Conventional Drug Therapy, With or Without Apheresis, in Patients With Homozygous Familial Hypercholesterolaemia. Circulation. 2017;136(11):1232-1234.

Disclosure: This review is intended for educational purposes. Treatment decisions should be individualized based on patient characteristics and current guidelines.

Search This Blog

Internal medicine